Telomir Pharmaceuticals (TELO) announced Telomir-1 has captured and stabilized both Silver and the highly reactive Silver in a biologically compatible form. The company said, “This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.” Telomir is advancing research and development to explore clinical applications of stabilized Silver complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw
- Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
- Telomir Pharmaceuticals files $150M mixed securities shelf
- Biotech Alert: Searches spiking for these stocks today
- Renovaro BioSciences appoints Fuentes as Chief Financial Officer
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue